PCK-HGFX7
Myocardial Ischemia
Helixmith Co., Ltd.gene_therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Myocardial Ischemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ranolazine East Carolina University | Phase 4 | A |
Acetylsalicylic Acid Rajaie Cardiovascular Medical and Research Center | Phase 4 | BBB |
ATENOLOL Xintong Pharmacy Company | Phase 4 | BBB |
Ranolazine East Carolina University | Phase 4 | BBB |
Nebido Sheffield Teaching Hospitals NHS Foundation Trust | Phase 4 | BB |
View all 35 →
Same molecule, other indications
PCK-HGFX7 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →